Applications published 8 August 2007

Pharmaceutical compsns comprising a camtothecin derivate
Novartis 1814520*

Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives
Vectura 1814521*

Method of formulation of the shape retentive aggregates of gel particles and their uses
Uluru 1814522*

Solid, oral drug form which has been designed to prevent misuse
Flamel Technologies 1814523*

Solid, oral, microparticulate dosage form which has been designed to prevent misuse
Flamel Technologies 1814524*

Stable lyophilised anthracycline glycosides
Sicor 1814525*

Oral solid dosage forms containing a low dose of estradiol
Bayer Schering Pharma Aktiengesellschaft 1814526*

Bilayer tablet comprising telmisartan and amlodipine
Boehringer Ingelheim Pharmaceuticals 1814527*

Process for making a highly compressible controlled delivery compsns of metformin
Rubicon Research Private 1814528*

Dosage form time-lagged of drugs for the therapy of insomnia
Jagotec 1814529*

Dihydropyrimidine microcapsule formulations
Sigmoid Biotechnologies 1814530*

Transdermal drug delivery system
Durect 1814531*

Topical application of muscarinic and opioid agents for treatment of tinnitus
El Khoury, George 1814532*

Treatment of the consequences of alcohol abuse, hepatitis and pancreatitis
Haehner, Thomas, Mueller-Enoch, Dieter 1814533*

Treatment of acne using derivatives of 5-aminolevulinic acid
Photocure 1814534*

Nitrosated and nitrosylated compounds, compsns and methods for the treatment of ophthalmic disorders
Nitromed 1814535*

Copper melphalan and copper tegafur used as anti-tumoural agents
Gavira Biopharmaceuticals 1814536*

Macrocyclic tertiary amine beta-sectretase inhibitors for the treatment of Alzheimer's disease
Merck 1814537*

Method of delivering nasal spray
Alcon 1814538*

Treatment of conditions caused by calcium abnormalities
Yale University 1814539*

Compsns useful to treat ocular neovascular diseases and macular degeneration
Nu-Tein 1814540*

Stable atorvastatin formulations
Dexcel Pharma Technologies 1814541*

Novel pharmaceutical compsns and the uses thereof for controlling the different forms of addiction to drugs
Trimaran1 1814542*

Methoda and compsns using immunomodulatory compounds for treatment and management of parasitic diseases
Celgene 1814543*

Cancer treatments
Cephalon 1814544*

Compounds and compsns as protein kinase inhibitors
IRM 1814545*

Pharmaceutical compsn comprising a macrolide T-cell immunomodulator and anti-photoaging agent
Novartis 1814546*

Method for treating HIV infection through co-administration of tipranavir and darunavir
Boehringer Ingelheim International 1814547*

Method for treating HIV infection through co-administration of tipranavir and reverset
Boehinger Ingelheim International 1814548*

Method for treating HIV infection through co-administration of tipranavir and UK-427, 857
Boehringer Ingelheim International 1814549*

N-sulphonylpiperidine cannabinoid receptor 1 antagonists
Bristol-Myers Squibb 1814550*

Pyridine derivatives for inhibiting human stearoyl-CoA-desaturase
Xenon Pharmaceuticals 1814551*

Compounds for treating protein-kinase mediated disorders
Astex Therapeutics; The Institute of Cancer Research: The Royal Cancer Hospital; Cancer Research Technology 1814552*

GTPase inhibitors and use thereof for controlling platelet hyperactivity
Children's Hospital Medical Centre; Girindus America 1814553*

Certain compounds, compsns and methods
Cytokinetics 1814554*

S-mirtazapine for the treatment of ho flush
NV Organon 1814555*

Methods of hormone treatment utilising ascending dose extended cycle regimens
Duramed Pharmaceuticals 1814556*

Use of a corticosteroid in association with a diuretic and an antacid for the treatment of vascular stenosis and the prevention of vascular restenosis
Universita" Degli Studi Del Piedmonte Orientale “Amedeo Avogadro” 1814557*

Methods and compsns for reducing neurodegeneration in amyotrophic lateral sclerosis
Yoo, Seo Hong 1814558*

Methods and compsns for protecting cells from ultra-sound-mediated cytolysis
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 1814559*

Antibiotic compounds, compsns and medical uses
Aventis Pharmaceuticals 1814560*

Therapeutic furopyrimidines and thienopyrimidines
Biocryst Pharmaceuticals 1814561*

Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
ND Partners; Prosi, Frank 1814562*

Platelet activation markers as predictors of disease and of response to therapy and for monitoring therapeutic progress
Bayer HealthCare 1814563*

Transmucosal oral delivery device
Izun Pharmaceuticals; Levine, William 1814564*

Use of pentamers for producing a medicament
Responsif 1814565*

Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
Sciclone Pharmaceuticals 1814566*

Use of modulators of EPHA2 and ephrina1 for the treatment and prevention of infections
Medimmune 1814567*

Combination cancer immunotherapy with co-stimulatory molecules
University of Southern California 1814568*

Glycolipids
Neose Technologies 1814569*

Methods for lowering HIF-1 medicated gene expression
Henry M Jackson Foundation 1814570*

In situ method for treatment and repair of meniscal injuries
Histogenics 1814571*

Prevention of vertical endoparasite infections
Bayer HealthCare 1814572*

Remodelling and glycopegylation of fibroblast growth factor (FGF)
Neose Technologies 1814573*

Adrenocorticotropic hormone analogues and related methods
University of Denver; University of Florida; Oklahoma Medical Research Foundation 1814574*

Methods and compsns for treating conditions
Skubatch, Hanna 1814575*

Combination therapies of HMGB and complement inhibitors against inflammation
Critical Therapeutics 1814576*

Use of BAFF to treat sepsis
The Washington University 1814577*

Compsns and methods for treatment of protein misfolding and protein aggregation diseases
University of Washington 1814578*

Mutated netrin-4, fragments thereof and their use as medicines
Centre National de la Recherche Scientifique; Institut des Vaisseaux et du Sang 1814579*

Methods of using IL-2 for adoptive immunotherapy and identification of tumour antigens
Fred Hutchinson Cancer Research Centre 1814580*

Stable formulations of peptides
Novo Nordisk 1814581*

A method of reducing drug-induced adverse side effects in a patient
Intercept Pharmaceuticals 1814582*

Combination approaches for generating immune responses
Novartis Vaccines and Diagnostics; The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 1814583*

Ligands that enhance endogenous compounds
Domantis 1814584*

Methods and materials for the inhibition of transplant rejection
The Scripps Research Institute 1814585*

Anti-properdin antibodies, and methods for making and using same
Amgen Frement 1814586*

Purposeful movement of human migratory cells away from an agent source
The General Hospital Corp 1814587*

Anti-infective lipopeptides
Cubist Pharmaceuticals 1814588*

Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
NV Organon 1814589*

Treatment of obesity and related disorders
Amylin Pharmaceuticals 1814590*

Bioactive compsns
Anadis 1814591*

Antiviral compsn
Hershline, Roger 1814592*

An oral preparation having improved bioavailability
Dong Wha Pharm 1814593*

Vector comprising polymer modified siRNA liposomes
IC Vec 1814594*

Treatment of cancer with a combination of an agent that perturbs the EGF signalling pathway and an oligonucleotide that reduces clusterin levels
The University of British Columbia 1814595*

Antisense antiviral compounds and methods for treating filovirus infection
AVI BioPharma 1814596*

RNAI modulation of the BCR0ABL fusion gene and uses thereof
Alnylam Pharmaceuticals 1814597*

Contrast agents to target extracellular matrix
GE Healthcare 1814598*

Combination therapy using transferrin fusion proteins comprising GLP-1
Biorexis Pharmaceutical 1814599*

Device for treating goods with the aid of an electric discharge
JE PlasmaConsuklt 1814600*

Methods and kits for aseptic filling of products
DePuy Spine 1814601*

Prodrugs of (2R)-2-propyloctanoic acid for treatment of stroke
Merck 1814838*

Immunotherapeutic agent
Stanford Rook 1814839*

Process for preparing haleohenoalkylnitrates
NocOx 1814840*

Ceramides and apoptosis-signalling ligand
MUSC Foundation for Research Development 1814841*

Method for preparing (meth) acrylic esters or anhydrides
Arkema France 1814842*

Stable crystalline modifications of DOTAP chloride
Merck Patent 1814843*

Method for the continuous production of alkyl amino acryl amides
Roehm 1814844*

Carboxamides and their use
Givaudan 1814845*

11beta-HSD1 inhibitors
Evotec 1814846*

Novel method for preparing 3-[5"-(3,4-bis-hydroxymethyl-benzyloxy)-2"-ethyl-2-propyl-biphenyl-4-yl]-penta-3-ol
Galderma Research & Development 1814847*

2,3,4-substituted-cyclopentanones as therapeutic agents
Allergan 1814848*

Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
Abbott 1814849*

New histone deacetylases inhibitors
DAC 1814850*

4-phenylsulphonamidopiperidines as calcium channel blockers
Euro-Celtique 1814851*

Hydroxybenzoate salts of metanicotine compounds
Targacept 1814852*

Hydroxybenzoate salts of metanicotine compounds
Targacept 1814853*

Cationic ceramides, and analogues thereof, and their use for preventing or treating cancer
MUSC Foundation for Research Development 1814854*

Dicarboxamide derivatives and their use as factor XA inhibitors
F Hoffmann-La Roche 1814855*

Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
Galapagos 1814856*

Isotopically marked quinoline derivatives as adenosin A3 receptor ligands
Sanofi-Aventis 1814857*

Novel crystalline forms of nelfinavir mesylate
Matrix Laboratories 1814858*

Methods for preparing indazole compounds
Pfizer 1814859*

Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
Schering 1814860*

Substituted 5-oxo pyrazoles and [1.2.4]triazoles as antiviral agents
Schering 1814861*

Vinylaminopyrazole derivatives as pesticides
Merial 1814862*

Indazole sulphonamide derivatives
AstraZeneca 1814863*

Nitro indazole derivatives
AstraZeneca 1814864*

Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
Athersys; Bannani, Youssef; Turney, Lawrence; Gleason, Elizabeth; Robarge, Michael 1814865*

Gonadotropin-releasing hormone receptor antagonists
Wyeth 1814866*

Aryl pyrimidyl compounds, pharmaceutical compsns comprising them, their use as antimicrobial agents
Institut Pasteur; Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique 1814867*

Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docataxel
Chatham Biotec 1814868*

Substituted amino acids as protein tyrosine phosphatase inhibitors
The Institute for Pharmaceutical Discovery 1814869*

Benzo-1,3-dioxanes for use in liquid crystal devices
QinetiQ 1814870*

Compounds that modulate ppary type receptors, and use thereof in cosmetic or pharmaceutical compsns
Galderma Research & Development 1814871*

Substituted [(phenylethanoyl)amino] benzamides and the use thereof in the treatment of inflammatory and cardio-vascular diseases
Bayer HealthCare 1814872*

5-sulphonyl-1-piperdinyl substituted indole derivatives as 5-HT6 receptor antagonists for the treatment of CNS disorders
Glaxo Group 1814873*

N-heterocyclic phthalic acid diamides as insecticides
Bayer CropScience 1814874*